Clinical characteristics and outcome of patients with invasive pneumococcal disease, Puy-de-Dôme, France, 1994-1998
- PMID: 11453589
- DOI: 10.1007/pl00011269
Clinical characteristics and outcome of patients with invasive pneumococcal disease, Puy-de-Dôme, France, 1994-1998
Abstract
A surveillance program for invasive pneumococcal disease was undertaken in Puyde-Dĵme, an administrative district of the region Auvergne in France, from 1 January 1994 to 31 December 1998. A total of 214 cases were identified. The annual incidence of invasive pneumococcal disease increased (P=0.04) from 5.5 in 1994 to 9.3 cases per 10(5) person-years in 1998. The highest incidences were for children <2 years of age (59.2 cases per 10(5) person-years) and for adults > or = 65 years (18 cases per 10(5) person-years). Clinical diagnoses, available in 200 patients, included acute pneumonia (62%), meningitis (10%), sepsis without focus (20%), and others (8%). The most frequent chronic medical conditions of the patients included smoking, alcoholism, cardiovascular and pulmonary diseases, and malignancies. Thirty-one percent of the isolates were nonsusceptible to penicillin. Penicillin resistance (MIC > or = 0.1 mg/l) was more frequent (P=0.02) in cancer patients. The overall case-fatality rate was 21.5%. Risk factors for death were age, sex, and underlying diseases of the patients, along with the severity of illness. These population-based findings should convince clinicians to offer pneumococcal vaccine to patients at high risk for invasive pneumococcal disease, thereby increasing vaccination coverage levels in France.
Similar articles
-
Impact of pneumococcal conjugate vaccines on burden of invasive pneumococcal disease and serotype distribution of Streptococcus pneumoniae isolates: an overview from Kuwait.Vaccine. 2012 Dec 31;30 Suppl 6:G37-40. doi: 10.1016/j.vaccine.2012.10.061. Vaccine. 2012. PMID: 23228356
-
[Invasive pneumococcal disease in Poland in 2010].Pol Merkur Lekarski. 2011 Aug;31(182):80-5. Pol Merkur Lekarski. 2011. PMID: 21936342 Polish.
-
The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta.N Engl J Med. 1995 Aug 24;333(8):481-6. doi: 10.1056/NEJM199508243330803. N Engl J Med. 1995. PMID: 7623880
-
Summary of invasive pneumococcal disease burden among children in the Asia-Pacific region.Vaccine. 2010 Nov 10;28(48):7589-605. doi: 10.1016/j.vaccine.2010.07.053. Epub 2010 Aug 1. Vaccine. 2010. PMID: 20674872 Review.
-
Streptococcus pneumoniae infections in the neonate.Pediatrics. 2003 Nov;112(5):1095-102. doi: 10.1542/peds.112.5.1095. Pediatrics. 2003. PMID: 14595052 Review.
Cited by
-
Clinical implications of pneumococcal serotypes: invasive disease potential, clinical presentations, and antibiotic resistance.J Korean Med Sci. 2013 Jan;28(1):4-15. doi: 10.3346/jkms.2013.28.1.4. Epub 2013 Jan 8. J Korean Med Sci. 2013. PMID: 23341706 Free PMC article. Review.
-
Cost-effectiveness analysis of pneumococcal conjugate vaccine 13-valent in older adults in Colombia.BMC Infect Dis. 2014 Mar 28;14:172. doi: 10.1186/1471-2334-14-172. BMC Infect Dis. 2014. PMID: 24679135 Free PMC article.
-
Initial management of and outcome in patients with pneumococcal bacteremia: a retrospective study at a Swiss university hospital, 2003-2009.Infection. 2011 Dec;39(6):519-26. doi: 10.1007/s15010-011-0218-1. Epub 2011 Nov 8. Infection. 2011. PMID: 22065426
-
African meningitis belt pneumococcal disease epidemiology indicates a need for an effective serotype 1 containing vaccine, including for older children and adults.BMC Infect Dis. 2010 Feb 10;10:22. doi: 10.1186/1471-2334-10-22. BMC Infect Dis. 2010. PMID: 20146815 Free PMC article.
-
Clinical and economic burden of invasive pneumococcal disease in adults: a multicenter hospital-based study.BMC Infect Dis. 2013 May 4;13:202. doi: 10.1186/1471-2334-13-202. BMC Infect Dis. 2013. PMID: 23641904 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical